NRG1抗体;NRG1 Antibody—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Mouse brain tissue, A172 cells, Primary antibody: P11826(NRG1 Antibody) at dilution 1/650, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P11826(NRG1 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

Neuregulin-1 (NRG1) antibodies are tools used to study the NRG1 signaling pathway, which plays critical roles in cellular processes such as proliferation, differentiation, and survival. NRG1 belongs to the epidermal growth factor (EGF) family and functions by binding to ErbB receptor tyrosine kinases, particularly ErbB3 and ErbB4. triggering downstream signaling cascades. This pathway is essential in developing and maintaining the nervous system, heart, and mammary glands. Dysregulation of NRG1 signaling has been implicated in various diseases, including cancer, schizophrenia, and cardiovascular disorders.

NRG1 antibodies are widely utilized in research to detect and quantify NRG1 isoforms (e.g., NRG1α and NRG1β) in tissues or cell lines via techniques like Western blotting, immunohistochemistry, and ELISA. They help elucidate NRG1's spatial and temporal expression patterns, shedding light on its physiological and pathological roles. For instance, in oncology, these antibodies aid in studying NRG1's dual role as both a tumor suppressor and promoter, depending on context and isoform expression. In neuroscience, they explore NRG1's involvement in synaptic plasticity and its potential link to psychiatric disorders.

Therapeutic antibodies targeting NRG1 or its receptors are under investigation, particularly in cancers with NRG1 gene fusions, which drive oncogenic signaling. However, challenges remain in specificity and minimizing off-target effects. Overall, NRG1 antibodies serve as vital reagents for unraveling the complexities of this multifaceted signaling axis and advancing translational applications.